Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, single arm, phase II study to evaluate the safety and efficacy of the neoadjuvant therapy before radical cystectomy of MIBC with sindilimab injection (IBI308)

Next Previous
X
Search
Trial Profile

An open, single arm, phase II study to evaluate the safety and efficacy of the neoadjuvant therapy before radical cystectomy of MIBC with sindilimab injection (IBI308)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Feb 2023 Results (n=15; Between Aug 2020 and Sep 2022) assessing the efficacy and safety of the sintilimab in neoadjuvant setting of muscle-invasive urothelial carcinoma of bladder, presented at the 2023 Genitourinary Cancers Symposium.
    • 04 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top